Related Experiment Video
Updated: Aug 16, 2025
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
LATE CHOROIDAL NEOVASCULAR COMPLICATIONS IN A PATIENT TREATED FOR RETINOBLASTOMA. A CASE REPORT
Insights
This case report details choroidal neovascularization (CNV) detection in a patient previously treated for bilateral retinoblastoma. Anti-VEGF treatment successfully reduced CNV and improved vision in the affected eye.
Area of Science:
- Ophthalmology
- Oncology
- Genetics
Background:
- Retinoblastoma is a common childhood eye cancer.
- Rb1 gene mutations are associated with hereditary retinoblastoma.
- Treatment for retinoblastoma includes laser therapy and chemotherapy.
Observation:
- A patient treated for bilateral retinoblastoma developed visual impairment at age 14.
- Choroidal neovascularization (CNV) was diagnosed in the macular region of the left eye.
- The CNV was located at the interface of the tumor scar and healthy retina.
Findings:
- Intravitreal bevacizumab (anti-VEGF) was administered three times.
- A reduction in CNV was observed after treatment.
- Visual function improved following the anti-VEGF therapy.
Implications:
- This case highlights the potential for late-onset complications after retinoblastoma treatment.
- Choroidal neovascularization is a treatable complication in post-retinoblastoma patients.
- Anti-VEGF therapy shows promise for managing CNV in this population.
Aim:
Case report of choroidal neovascularization (CNV) detection in patient who was treated for bilateral retinoblastoma in early childhood.
Material And Methods:
Patient at 1.5 years of age treated for endophytic retinoblastoma stage 4 (according to the Reese-Ellsworth classification) bilaterally, with a positive mutation in the Rb1 gene. After undergoing bilateral retinal laser treatment and 6 cycles of systemic chemotherapy, the tumor remained inactive without other complications. At the age of 14, the boy developed visual impairment in his left eye with metamorphosis. Based on a local finding and other auxiliary examinations, he was diagnosed with CNV in the macular area at the interface of the tumor scar and the healthy retina of the left eye.
Results:
After three applications of anti-VEGF (antibodies blocking vascular endothelial growth factor) substance intravitreally (bevacizumab 1.2 mg), there was a reduction in CNV and also an improvement in visual function.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:25Glaucoma: Overview